TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that it received approval from the National Medical Products Administration of China for the production and registration of Tolterodine Tartrate Sustained-release Capsules, a treatment for overactive bladder. This approval marks the third such recognition for SSY Group among PRC entities, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating products that address various medical needs, with a particular emphasis on drug production and registration in China.
Average Trading Volume: 14,001,176
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.09B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.